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Abstract
Background: Probucol is a unique hypolipidemic agent that decreases high density lipoprotein cholesterol (HDL-
C). However, it is not definite that whether probucol hinders the progression of atherosclerosis by improving HDL
function.
Methods: Eighteen New Zealand White rabbits were randomly divided into the control, atherosclerosis and
probucol groups. Control group were fed a regular diet; the atherosclerosis group received a high fat diet, and the
probucol group received the high fat diet plus probucol. Hepatocytes and peritoneal macrophages were isolated
for [3H] labeled cholesterol efflux rates and expression of ABCA1 and SR-B1 at gene and protein levels; venous
blood was collected for serum paraoxonase 1, myeloperoxidase activity and lipid analysis. Aorta were prepared for
morphologic and immunohistochemical analysis after 12 weeks.
Results: Compared to the atherosclerosis group, the paraoxonase 1 activity, cholesterol efflux rates, expression of
ABCA1 and SR-BI in hepatocytes and peritoneal macrophages, and the level of ABCA1 and SR-BI in aortic lesions
were remarkably improved in the probucol group, But the serum HDL cholesterol concentration, myeloperoxidase
activity, the IMT and the percentage plaque area of aorta were significantly decreased.
Conclusion: Probucol alleviated atherosclerosis by improving HDL function. The mechanisms include accelerating
the process of reverse cholesterol transport, improving the anti-inflammatory and anti-oxidant functions.
Keywords: probucol, high density lipoprotein function, reverse cholesterol transport, Paraoxonase 1,
Myeloperoxidase
Background
Numerous epidemiological studies reported an inverse
relationship between high density lipoprotein cholesterol
(HDL-C) and the incidence of cardiovascular disease.
The national cholesterol education program adult treat-
ment panel III guidelines identified that low HDL-C (<40
mg/dl) is a major risk factor for coronary heart disease
(CHD), independent of triglycerides and total cholesterol;
for every 1 mg/dl increase in HDL-C, the predicted inci-
dence of coronary events decreases by 2% in men and 3%
in women [1,2].
However, the relationships between HDL and CHD
risk are more complex beyond the serum HDL-C levels.
The Milano people who carry the apolipoprotein A-I
Milano mutant have low serum HDL-C levels but do not
confer an increased cardiovascular risk [3]. Additionally,
the torcetrapib, an inhibitor of potent cholesteryl ester
transfer protein (CETP), markedly increased the serum
HDL-C levels, but the risk of deaths and cardiac events
had been increased simultaneously in patients receiving
tocetrapib [4]. Hausenloy and his colleagues found that
HDL isolated from patients with CHD was ineffective
as an antioxidant, but paradoxically, appeared to be pro-
oxidant [5]. Given this complexity, it is not surprising
that a single assay of serum steady-state HDL-C levels
does not necessarily correlate with HDL function. Struc-
tural modification and composition alteration of HDL
may lead to HDL loss of normal biological function, even
though HDL-C levels is normal which still failed to inhi-
bit atherosclerosis.
Probucol is a unique cholesterol lowering drug with
anti-oxidant and anti-inflammatory properties that
decreases HDL-C levels [6]. Multivitamins and probucol
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(MVP) trial revealed that probucol reduces coronary
restenosis after percutaneous transluminal coronary
angioplasty [7]. And probucol observational study illu-
minating therapeutic impact on vascular events (POSI-
TIVE) showed that probucol was useful in lowering the
risk of cardiovascular events in secondary prevention in
spite of causing a decrease in HDL-C levels [8].
Although probucol decreases HDL-C levels, it shows
greatly controlled progression of atherosclerosis. We
concluded that probucol may improve HDL function.
The major cardiovascular protective effects of HDL
function may be attributed to its role in reverse cholesterol
transport (RCT), anti-oxidant and anti-inflammation and
so on [9]. ATP binding cassette transporter A1 (ABCA1)
and scavenger receptor class B type I (SR-BI) play the key
role in the process of RCT, high expression of ABCA1 and
SR-BI can reflect the atheroprotective function of HDL
[10]. So we examined whether probucol promoted RCT
by up-regulating the expression of ACBA1 and SR-BI in
peritoneal macrophages and hepatocytes. Paraoxonase 1
(PON1) and Myeloperoxidase (MPO) are enzymes closely
associated with HDL anti-oxidant function. PON1 contri-
butes to the anti-oxidant effects of HDL and its activity is
inversely related to the risk of cardiovascular diseases [11].
MPO participates in HDL-oxidation and its activity is
positive correlation with the risk of cardiovascular diseases
[12]. And we considered probucol may improve HDL
anti-oxidant function by affecting serum PON1 and MPO
activity.
Results
Effects of probucol on serum lipid and body weight
There were no significant difference in serum lipid
levels and body weight among the three groups at the
baseline. At the end of the research, the results of the
serum lipid suggested that hypercholesterolemia model
was successfully established, serum triglyceride (TG),
total cholesterol (TC), LDL-C and HDL-C in
atherosclerosis group were significantly higher than con-
trol group. Serum lipids were also increased in probucol
group as compared with control group, but TC, LDL-C
and HDL-C in probucol group were significantly lower
than atherosclerosis group. There was no doubt that
probucol reduced HDL quantity. There was no signifi-
cant difference in body weight among the three groups
throughout the experiment (Table 1).
Effects of probucol on restraining aortic atherosclerosis
The thoracic aortic IMT and the percentage plaque area
(surface area of plaque/surface area of whole intima)
were significantly higher in the two cholesterol-fed
groups than control group, which indicated that the
expected atherosclerotic model were successful. Addi-
tionally, IMT and the percentage plaque area in probu-
col group were lower than atherosclerosis group, which
revealed that probucol hindered the process of athero-
sclerosis (Figure 1).
Effects of probucol on cholesterol efflux rate in
hepatocytes and peritoneal macrophages
We measured the HDL-induced cholesterol efflux rate
in hepatocytes and peritoneal macrophages. The results
showed that the cholesterol efflux rate of hepatocytes
and peritoneal macrophages in atherosclerosis group
were about half of control group. However, cholesterol
efflux rate of hepatocytes and peritoneal macrophages in
probucol group were about two-fold higher than athero-
sclerosis group. (Figure 2)
ABCA1 or SR-BI mRNA and protein expressions in
hepatocytes or peritoneal macrophages
We found that mRNA expressions of ABCA1 and SR-BI
in hepatocytes were significantly lower in atherosclerosis
group than in control group, but they were significantly
higher in probucol group than in atherosclerosis group.
Furthermore, the result also showed that mRNA
Table 1 Serum lipid and body weight profiles in three groups’ rabbits
TG TC LDL-C HDL-C BW(kg)
Control group
0 week 1.04 ± 0.19 1.85 ± 0.12 1.00 ± 0.20 0.47 ± 0.12 2.01 ± 0.08
12 week 1.02 ± 0.15 1.79 ± 0.21 1.09 ± 0.23 0.45 ± 0.12 2.77 ± 0.04
Atherosclerosis group
0 week 1.10 ± 0.14 1.77 ± 0.15 0.99 ± 0.20 0.48 ± 0.12 2.07 ± 0.06
12 week 1.58 ± 0.25* 23.26 ± 3.30* 18.09 ± 4.04* 1.11 ± 0.09* 2.88 ± 0.08
Probucol group
0 week 1.02 ± 0.15 1.76 ± 0.11 1.00 ± 0.15 0.43 ± 0.10 2.03 ± 0.04
12 week 1.60 ± 0.17 16.70 ± 0.70# 13.79 ± 2.01# 0.51 ± 0.06 # 2.72 ± 0.21
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HDL-C: high-density lipoprotein cholesterol; BW: body weight. Units for TC, TG,
LDL-C and HDL-C are mmol/L and BW is kg. All values are presented as mean ± S.D. (n = 6).
* P < 0.05, compared to control group; # P < 0.05, compared to atherosclerosis group.
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expression of SR-BI was higher than ABCA1 in hepato-
cytes (Figure 3A).
At the same time, we measured ABCA1 and SR-BI
protein expressions in hepatocytes and peritoneal
macrophages. The results showed that ABCA1 and SR-
BI protein expressions in probucol group both in hepa-
tocytes and peritoneal macrophages were higher than
in atherosclerosis group. More interesting, we found
that protein expression of ABCA1 was higher than SR-
BI in peritoneal macrophages, but expression of SR-BI
was higher than ABCA1 in hepatocytes. Furthermore,
we observed that as compare with atherosclerosis
group, protein expressions of ABCA1 in hepatocytes
and peritoneal macrophages on probucol group were
increased by 44.96% and 52.15% respectively; and SR-
BI in hepatocytes and peritoneal macrophages on pro-
bucol group were increased by 98.14% and 79.92%,
respectively (Figure 3B-C).
Immunohistochemical localization of ABCA1 and SR-BI in
Aortic atherosclerosis lesions
In the control group, there were no atherosclerosis pla-
ques and immunohistochemical staining in aortic walls for
ABCA1 and SR-B1. So we just analyzed the percentage of
the positive area in the two cholesterol-fed groups. As
shown in the Figure 4, ABCA1 (deep brown) and SR-B1
(deep red) protein could be detected in aortic athero-
sclerosis plaques. We found that ABCA1 and SR-BI pro-
tein positive area were significantly higher in probucol
group than in atherosclerosis group (Figure 4C).
Effects of probucol on serum PON1 and MPO activity
To study the effect of probucol on anti-oxidant and
anti-inflammation properties of HDL, we detected the
serum PON1 and MPO activity. Compared with the
control group, the serum PON1 activity was extremely
lower in atherosclerosis group, and serum PON1 activity
was significantly increase when treated by probucol. In
addition, extremely low MPO activity was found in the
samples obtained from control group, and the MPO
activity in atherosclerosis group showed significantly
higher in comparison to the probucol group (Figure 5).
Discussion
The most important theory revolved around the role of
HDL function is RCT, in which excess cholesterol
effluxes to HDL and ultimately returns to the liver for
metabolism. The process of RCT is extremely compli-
cated: At first, cholesterol efflux from macrophages and
then lipid-poor ApoA-I quickly acquires it via the
Figure 1 The thoracic aortic IMT and the percentage plaque
area (%) were decreased with the treatment of probucol.
*** P < 0.001, compared with control group; ### P < 0.001,
## P < 0.01 compared with atherosclerosis Group.
Figure 2 Cholesterol efflux rate of hepatocytes and peritoneal
macrophages were increased in probucol group. *** P < 0.001,
compared with control group; ### P < 0.001, compared with
atherosclerosis group.
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ABCA1 transporter. Lipidation of the lipid-poor ApoA-I
and cholesterol complex generates nascent (pre-b) HDL
[13]. Subsequently, lecithin cholesterol acyl transferase
(LCAT) mediated cholesterol esterification generates
small HDL3 particles; small HDL3 can be converted to
large mature HDL2 in turn upon CETP [14]. At last,
these mature HDL2 transfer its cholesterol to the liver
directly via SR-BI and excrete cholesterol through the
bile (Figure 6) [15].
The best-recognized atheroprotective function of HDL
is the promotion of cholesterol efflux from cells, parti-
cularly from macrophages and hepatocytes, because
macrophages are the primary cell type to accumulate
cholesterol within the atherosclerotic plaque and hepa-
tocytes are the main cell type to excrete cholesterol
through the bile [16]. In our research, we found that
probucol increased the cholesterol efflux capacity of
Figure 3 Expressions of ABCA1 and SR-B1 were up-regulated
by probucol. (A) Hepatocytes ABCA1 and SR-B1 mRNA expression
quantified by real-time RT-PCR. (B) ABCA1 protein expression of
hepatocytes and peritoneal macrophages determined by flow
cytometry. (C) SR-B1 protein expression of hepatocytes and
peritoneal macrophages determined by flow cytometry.* P < 0.05,
** P < 0.01, *** P < 0.001 compared with control group; # P < 0.05,
## P < 0.01, ### P < 0.001 compared with atherosclerosis group.
Figure 4 Immunochemical staining of ABCA1 and SR-BI in
aortic plaques. Representative light microscopy images of aortic
plaques (×40, below ×100). (A) ABCA1 staining (deep brown) in
aortic plaque. (B) SR-BI staining (deep red) in aortic plaque. (C)
ABCA1 and SR-BI staining positive area percentage were significantly
increased in probucol group compared with atherosclerosis group.
## P < 0.01, ### P < 0.001 compared with atherosclerosis group.
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peritoneal macrophages, which could accelerate choles-
terol effusing from macrophages that reduce cholesterol
accumulating in artery wall. Additionally, probucol also
increased the cholesterol efflux capacity of hepatocytes,
which accelerated liver cells excreting cholesterol into
the bile and decreased circulating lipids level.
ABCA1 is an efflux transporter for cholesterol and
phospholipids, which is essential for the formation of
HDL. Tangier disease patients and ABCA1−/− mice fail to
form discoid or spherical HDL, which exhibit abnormal
lipid deposition in various tissues [17]. In macrophages,
ABCA1 facilitates the transfer of the cholesterol to apoA-
I, and then the lipidated apoA-I/ABCA1 complex dissoci-
ate and release the nascent HDL [18]. In our research, we
found that probucol up-regulated the expression of
ABCA1 in macrophages. It indicated that probucol
accelerated cholesterol effusing from macrophages by
ABCA1, which might promote further releasing of nas-
cent HDL that has much more strong binding capacity to
cholesterol. In the liver cells, highly expression of liver
ABCA1 is to facilitate biliary excretion of cholesterol,
which plays an important role in lipid homeostasis [19].
We found that probucol also promoted cholesterol
excreting through the bile by ABCA1, which played an
important role in reducing circulating cholesterol.
SR-BI also plays an important role in HDL metabolism.
The catabolism of HDL is regulated in part by cholesterol
ester removal or delipidation by SR-BI, which can con-
trols the structure, composition, and concentration of
HDL [20]. We found that probucol up-regulated the
expression of SR-BI in macrophages and accelerate cho-
lesterol effusing from macrophages. Rigotti and collea-
gues reported that they found abnormally large,
heterogeneous, apoE-enriched, HDL like particles in SR-
BI deficient mice, whose total serum cholesterol doubled
[21]. Furthermore, the SR-BI deficiency greatly reduced
the clearance of HDL cholesterol from serum [22].
Unfortunately, whether probucol reduce HDL-C levels by
up-regulating expression of SR-BI in hepatocytes is
unclearly. We found that probucol significantly increased
expressions of SR-BI in hepatocytes. The increased SR-BI
expression resulted in enhanced binding of large spheri-
cal HDL to the liver cells, which can speed up catabolism
of HDL, and reduce serum HDL level. It may be the
mechanism that probucol significant down-regulate
HDL-C levels, but it didn’t mean probucol declined HDL
function, On the contrary it indicated probucol enhanced
RCT and the metabolism of HDL.
HDL functions such as anti-oxidant and anti-inflam-
mation are also important to restrain atherosclerosis.
Native LDL has little effect on cells of the arterial wall,
whereas oxidatively modified forms of LDL induce
numerous proatherosclerotic effects [23]. HDL plays an
important role in protecting against LDL oxidative mod-
ification, but dysfunctional HDL accumulates oxidants
that promoting the formation of LDL-derived oxidized
lipids and oxidation of LDL [24]. The enzyme PON1
plays the key role to the anti-oxidative effects of HDL.
In our research, we found that rabbits treated by probu-
col have higher PON1 activity than atherosclerosis
group. Navab and colleagues reported a failure of HDL
to protect LDL from oxidation in patients with coronary
atherosclerosis, which they proposed was due to their
low serum PON1 activity despite relatively normal
HDL-C levels [25]. PON1 can prevent lipid-peroxide
accumulation on LDL and protect LDL from oxidative
modification. Serum PON1 activity is lower in subjects
prone to development of atherosclerosis such as in
hypercholesterolemia disease [26]. Furthermore, some
studies have proposed that PON1 may first associate
Figure 5 Serum PON1 and MPO activity. (A) Serum PON1 activity
was significantly enhanced in probucol group as compared with
atherosclerosis group. (B) Serum MPO activity was significantly
reduced in probucol group as compared with atherosclerosis group.
*** P < 0.001 compared with control group; ## P < 0.01, ### P <
0.001 compared with atherosclerosis group.
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with smaller HDL3, which are subsequently transformed
into larger HDL2 particles. In this context, PON1 would
be following the normal metabolic course of HDL in
which remodelling leads to an increase in particle size,
notably due to the accumulation of lipid components
[27,28]. High PON1 activity may improve HDL anti-oxi-
dant function.
Increasing evidences suggest that HDL is subjected to
oxidation in lesion material that reverses the atheropro-
tective function [29]. In vitro studies demonstrated that
MPO catalyzes oxidative modification of HDL leading to
the development of dysfunctional proinflammatory and
proatherogenic HDL [30]. MPO has been detected in
human atherosclerotic lesions and high serum MPO is
reported to be a risk factor for early adverse cardiac
events in patients with acute coronary syndromes [31].
In addition, MPO was injected into mice led to signifi-
cant reductions in RCT to the serum and fecal compart-
ments, which demonstrating a direct effect of MPO on
RCT in vivo[32]. In our research, we found probucol
significantly decreased MPO activity, which in turn may
reduce HDL oxidative modification and improve the
process of RCT.
Conclusions
In summary, probucol increased the expression of
ABCA1 and SR-BI in macrophages and hepatocytes,
which speeded up the process of RCT. Furthermore,
Figure 6 Process of RCT and HDL metabolism. Probucol up-regulate expression of ABCA1 and SR-B1 both in hepatocytes and peritoneal
macrophages. (red+mean up-regulated the receptor expression)
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probucol improved HDL anti-oxidant function by
increasing serum PON1 activity. Probucol also reduced
oxidative and inflammatory modification of HDL by
decreasing serum MPO activity. Probucol reduced HDL-




Eighteen New Zealand white male rabbits (four months
old, weighing 1.89 kg ~2.15 kg) provided by the Labora-
tory Animal Centre of Southern Medical University and
individually housed in air-conditioned room. After a 7-
day adaptation period, they were randomly divided into
three groups: control group animals (n = 6) were fed a
regular diet for 12 weeks; the atherosclerosis group (n =
6) were fed a high fat diet supplemented with 1% (w/w)
cholesterol, 8% lard (w/w) and 0.05% cholate (w/w); and
the probucol group were fed with the same high fat diet
plus probucol (400 mg/ kg/day). Each rabbit consumed
about 120 g of food daily. Rabbits were caged individu-
ally with water ad libitum for 12 weeks, and maintained
on a 12-h day/night cycle. Animal procedures were per-
formed in accordance with guidelines set by the Animal
Experiment Committee of Southern Medical University
Guangzhou, China.
Serum lipid, PON1 and MPO activity analyses
Serum triglycerides (TG), total cholesterol (TC), low-
density lipoprotein cholesterol (LDL-C) and HDL-C
concentrations were measured with an automated bio-
chemical analyzer (Type AU5421, Olympus, Japan) at
the baseline and at the end of the study.
Serum PON1 activity was assayed with the method
reported by Beltowski, using the synthetic substrate phenyl
acetate (Sigma Co, American) [33]. PON1 activity towards
phenyl acetate was determined by measuring the initial
rate of substrate hydrolysis within the assay mixture
(3 mL) containing 2 mM phenyl acetate, 2 mM CaCl2, and
10 μL of plasma in 100 mM Tris-HCl (pH 8.0). Absor-
bance was monitored for 90 seconds at 270 nm and
enzyme activity was calculated from the E270 of phenyl
acetate (1,310/M/cm) and expressed in U/mL (where 1 U
of arylesterase hydrolyzes 1 μmol of phenyl acetate/min).
MPO activity was measured by a MPO determination
kit (Jiancheng Bioengineering Co) using commercially
available reagents, according to the manufacturer’s
instructions. Briefly, the serum samples were incubated
in a 50 mM sodium phosphate buffer containing 1.5 M
hydrogen peroxide and 0.167 mmol O-dianisidine dihy-
drochloride for 30 min. The increase in absorbance at
460 nm was recorded with the use of a spectrophot-
ometer and the Enzymatic activity was calculated from
E460 = 11300/M/cm. A unit of MPO activity is defined as
the amount of enzyme degrading 1 μmol H2O2 per min-
ute at 37°C.
Isolation of hepatocytes and peritoneal macrophages
At the end of 12 weeks of the experiment, rabbits were
anesthetized by 2% pentobarbital. Under sterile condi-
tions, the parenchymal hepatocytes were isolated by clas-
sic in situ two steps perfusion of the liver with
collagenase IV (0.05%) by enzyme digestion with collage-
nase II (2 mg/ml). The peritoneal macrophages were col-
lected by peritoneal lavage with 200 ml PBS and purified
by adherent method. Subsequently, using a modified
method described by Zhao et al [34].
Assay of HDL-mediated cholesterol efflux rate
Experiments were performed as previously described
[35]. Rabbit peritoneal macrophages and hepatocytes
were respectively seeded in medium with 0.2% BSA and
antibiotics cultured to 2 × 105 cells/ml. Subsequently,
culture medium was replaced for 24 h with a medium
containing 0.2% BSA, 30 μg/ml Ox-LDL, and 1 μCi/ml
[1a, 2a-3H]-cholesterol (Perkin-Elmer) in DMEM/F12.
After cholesterol loading, cells were washed twice with
serum-free medium. Cells were incubated in DMEM/F12
with cAMP (0.3 mmol/L) for the next 12 h. And then,
apoA-I (10 ug/ml) was added to promote free cholesterol
efflux for 4 h. the incubation medium was collected and
centrifuged before counting radioactivity. The cell mono-
layer was washed with PBS and lysed with 1 ml of NaOH
(0.1 mol/L). The radioactivity of medium and cell lysates
was measured by liquid scintillation spectrometry (Beck-
man Instruments, Inc.). The cholesterol efflux rate was
expressed as the medium [3H] cholesterol radioactivity as
a percentage of total [3H] cholesterol radioactivity (cells
plus medium). Individual efflux values were calculated as
the averages of 3 determinations in different wells.
Analyses of ABCA1 and SR-BI mRNA in liver by real-time
PCR
Liver tissue was snap-frozen in liquid nitrogen until RNA
extraction. Tissues were then powdered in liquid nitrogen.
The quantitative analyses of ABCA1 and SR-B1 mRNA
level on rabbit liver tissues were performed by quantitative
real-time polymerase chain reaction (RT-PCR).Total RNA
was extracted from the frozen liver tissues by using RNA
Trizol reagent (Gibco RRL, Gaithersburg, USA). Then
first-strand cDNA was synthesized by using PrimeScript
RT Reagent Kit (Takara, China) according to the instruc-
tion from manufacture. The quantitative RT-PCR was
performed on iQ5 Real Time PCR Detection System (Bio-
Rad, American) using AllinOne™ Q-PCR Mix (GeneCo-
poeia Inc, American). Expression levels of the target genes
generated standard curves were normalized against an
endogenous reference gene glyceraldehydes 3-phosphate
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dehydrogenase (GAPDH). The specific primer sequences
were listed in the following pattern: (1) ABCA1: forward
primer: 5’-GAT GGC AAT CAT GGT CAA TGG -3’,
reverse primer: 5’-AGC TGG TAT TGT AGC ATG TTC
CG-3’ yielding a 201-bp size product; (2) SR-BI: forward
primer: 5’-CAG TGG GCA TTG TGT CCT GTC -3’,
reverse primer: 5’-GGC TCA GTG CAG GCT GAT
GTC-3’ yielding a 286-bp size product; and (3) GAPDH:
forward primer: 5’-GGA GCC AAA AGG GTC ATC-3’,
reverse primer: 5’-CCA GTG AGT TTC CCG TTC-3’
yielding a 346-bp size product. PCRs for each sample were
performed in duplicate, and the relative gene expressions
were analyzed as described previously [36].
Analyses of ABCA1 and SR-BI protein expression by flow
cytometer
The protein assay of ABCA1 and SR-B1 in peritoneal
macrophages and hepatocytes were performed as pre-
viously described by Pirillo et al [37]. The suspension of
peritoneal macrophages and hepatocytes were respectively
mixed with the antibody of ABCA1 or SR-B1(Santa Cruz
Biontechnology, Inc) for 60 min at room temperature in
the test tubes. The mixture was then washed two times
with PBS and added the antibody labelled PE fluorescence
(Seretec, Inc). After 30 min ABCA1/ SR-B1exprssion was
measured by flow cytometer (BD FACSCalibur) and
expressed as an average level in every hundred detected
cells.
Quantification of aortic atherosclerosis, histology and
immunohistochemistry
All segments were embeded in paraffin and cut into 4-μm
cross sections and stained with hematoxylin and eosin
(H&E) for histological examination. The percentage pla-
que area, which was defined as surface area of plaque/sur-
face area of whole intima, and the aortic intima-media
thickness (IMT) were calculated for evaluating the degree
of aortic atherosclerosis.
Experiments were performed as previously described
[38]. Immunostaining for ABCA1 (Boster Biotechnology
Co. Ltd China) and SR-BI (Abcam Co.Ltd American) was
performed in paraffin-embedded Aortic atherosclerosis
sections using the specific antibody and a Strept Avidin-
Biotin Complex (SABC) Antibody binding was visualized
with SABC kits (Boster Biotechnology Co. Ltd), Diamino-
benzidine (DAB) and 3-Amino-9-Ethylcarbazole (AEC)
were used as the chromogen and Mayer’s hematoxylin as
the nuclear counterstain. The sections were dehydrated,
cleared, mounted and performed by morphometric analy-
sis. All sections (H&E and immunostained) for micro-
scopic quantification were captured under an Olympus
BX51 light microscope equipped with a DP70 digital
camera (Olympus, Tokyo, Japan) and were measured
with Image pro plus 6.0 special image analysis software
(Media Cybernetics Co, American).
Statistical analysis
Data are presented as mean ± S.E.M. A one-way ANOVA
was used for analyzing differences in variables between
groups at the same time point. When P was ≤ 0.05, the
least significant difference method was used for compari-
son. An independent sample t-test was used for analyzing
the differences in variables between two groups at the
same time point. SPSS 13.0 software was used for statisti-
cal analysis with P < 0.05 indicating a statistically signifi-
cant difference.
Abbreviations
HDL-C : High density lipoprotein cholesterol; LDL-C Low-density lipoprotein
cholesterol; VLDL : Low-density lipoprotein cholesterol ; TC : total cholesterol;
TG : Triglyceride; PON1 : Paraoxonase 1; MPO : Myeloperoxidase; RT-PCR :
Real-Time Reverse transcription polymerase chain reaction; FACS : flow
cytometer; ABCA1 : ATP binding cassette transporter A1; SR-BI : scavenger
receptor class B type I; IMT : intima media thickness; CHD : Cardiovascular
heart disease; Apo-AI : apolipoprotein-AI; CETP : cholesteryl ester transfer
protein; LCAT : lecithin cholesterol acyl transferase; RCT : reverse cholesterol
transport,.
Acknowledgements
This work was supported by the Guangdong Scientific and Technological
Grant (No. 2008B030301158) and the key foundation of Nanfang Hospital
(No. 2008A003).
Authors’ contributions
ZGG was responsible for the experimental design, supervising the project,
data analysis and revising the manuscript. JKZ carried out all aspects of
experiments, data analysis and drafted the manuscript. CL was involved in
pathohistology, immunoassays and all samples collected. ZKW participated
in Constructed Animal models, collected blood sample, assayed cholesterol
efflux rate and RT-PCR. YWL, YT were involved in Cell culture, flow cytometer
and supervising the project. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 October 2011 Accepted: 12 November 2011
Published: 12 November 2011
References
1. National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III):
Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation
2002, 106:3143-3421.
2. Franceschini G: Epidemiologic evidence for high-density lipoprotein
cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001,
88(12):9N-13N.
3. Gomaraschi M, Baldassarre D, Amato M, Eligini S, Conca P, Sirtori CR,
Franceschini G, Calabresi L: Normal vascular function despite low levels of
high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I
(Milano) mutant. Circulation 2007, 116:2165-2172.
4. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M,
Sendon JL, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA,
Fisher MR, Tall AR, Brewer B: Effects of Torcetrapib in Patients at High Risk
for Coronary Events. N Engl J Med 2007, 357:2109-2122.
Zhong et al. Lipids in Health and Disease 2011, 10:210
http://www.lipidworld.com/content/10/1/210
Page 8 of 9
5. Hausenloy DJ, Yellon DM: Targeting residual cardiovascular risk: raising
high-density lipoprotein cholesterol levels. Postgrad Med J 2008,
84(997):590-598.
6. Yamashita S, Matsuzawa Y: Where are we with probucol: a new life for an
old drug? Atherosclerosis 2009, 207(1):16-23.
7. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S,
Bilodeau L, Nattel S, Guise P: Probucol and multivitamins in the
prevention of restenosis after coronary angioplasty. N Engl J Med 1997,
337:365-732.
8. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M,
Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents
secondary cardiovascular events: a cohort study of patients with
heterozygous familial hypercholesterolemia in Japan. J Atheroscler
Thromb 2008, 15(6):292-303.
9. Hazen S: HDL structure, function, therapeutics, and imaging. Arterioscler
Thromb Vasc Biol 2010, 30(2):138.
10. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE:
HDL biogenesis and functions: Role of HDL quality and quantity in
atherosclerosis. Atherosclerosis 2010, 208(1):3-9.
11. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-
Kalimanovska V, Topic A, Zeljkovic A, Stefanovic A, Zunic G: Association of
oxidative stress and PON1 with LDL and HDL particle size in middle-
aged subjects. Eur J Clin Invest 2007, 37(9):715-723.
12. Heinecke JW: The role of myeloperoxidase in HDL oxidation and
atherogenesis. Curr Atheroscler Rep 2007, 9(4):249-251.
13. Duffy D, Rader DJ: Update on strategies to increase HDL quantity and
function. Nat Rev Cardiol 2009, 6(7):455-463.
14. Movva R, Rader DJ: Laboratory assessment of HDL heterogeneity and
function. Ann Biol Clin (Paris) 2009, 67(1):7-21.
15. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein:
a new therapeutic target at the crossroads of dyslipidemia,
inflammation, and atherosclerosis. Pharmacol Rev 2006, 58(3):342-374.
16. Movva R, Rader DJ: Laboratory assessment of HDL heterogeneity and
function. Ann Biol Clin (Paris) 2009, 67(1):7-21.
17. Hiroshi N: Latest Insights into High Density Lipoprotein Functions. The
Endocrinologist 2009, 19(4):179-186.
18. Orsó E, Broccardo C, Kaminski WE, Böttcher A, Liebisch G, Drobnik W,
Götz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani MF,
Rothe G, Lackner KJ, Chimini G, Schmitz G: Transport of lipids from golgi
to plasma membrane is defective in tangier disease patients and Abc1-
deficient mice. Nat Genet 2000, 24(2):192-196.
19. Neufeld EB, Stonik JA, Demosky SJ Jr, Knapper CL, Combs CA, Cooney A,
Comly M, Dwyer N, Blanchette-Mackie J, Remaley AT, Santamarina-Fojo S,
Brewer HB Jr: The ABCA1 transporter modulates late endocytic
trafficking: insights from the correction of the genetic defect in Tangier
disease. J Biol Chem 2004, 279(15):15571-15578.
20. Cavelier LB, Qiu Y, Bielicki JK, Afzal V, Cheng JF, Rubin EM: Regulation and
activity of the human ABCA1 gene in transgenic mice. J Biol Chem 2001,
276(21):18046-18051.
21. Zannis VI, Chroni A, Krieger M: Role of apoA-I, ABCA1, LCAT, and SR-BI in
the biogenesis of HDL. J Mol Med 2006, 84(4):276-294.
22. Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, Kane J,
Krieger M, Zannis VI: Binding of high density lipoprotein (HDL) and
discoidal reconstituted HDL to the HDL receptor scavenger receptor
class B type I. Effect of lipid association and APOA-I mutations on
receptor binding. J Biol Chem 2000, 275(28):21262-21271.
23. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M: A targeted
mutation in the murine gene encoding the high density lipoprotein
(HDL) receptor scavenger receptor class B type I reveals its key role in
HDL metabolism. Proc Natl Acad Sci USA 1997, 94(23):12610-12615.
24. Out R, Hoekstra M, Spijkers JA, Kruijt JK, van Eck M, Bos IS, Twisk J, Van
Berkel TJ: Scavenger receptor class B type I is solely responsible for the
selective uptake of cholesteryl esters from HDL by the liver and the
adrenals in mice. J Lipid Res 2004, 45(11):2088-2095.
25. Mackness MI, Durrington PN: HDL, its enzymes and its potential to
influence lipid peroxidation. Atherosclerosis 1995, 115(2):243-253.
26. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert
potent protection of atherogenic LDL against oxidative stress. Arterioscler
Thromb Vasc Biol 2003, 23(10):1881-1888.
27. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI: Serum
paraoxonase activity in patients with type 1 diabetes compared to
healthy controls. Eur J Clin Invest 2002, 32(4):259-264.
28. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ,
Castellani LW, Brennan ML, Lusis AJ, Fogelman AM, La Du BN: Mildly
oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.
J Clin Invest 1997, 99(8):2005-2019.
29. Rye KA, Clay MA, Barter PJ: Remodelling of high density lipoproteins by
plasma factors. Atherosclerosis 1999, 145(2):227-238.
30. K Nicholls SJ, Zheng L, Hazen SL: Formation of dysfunctional high-density
lipoprotein by myeloperoxidase. Trends Cardiovasc Med 2005,
15(6):212-219.
31. Niu X, Zammit V, Upston JM, Dean RT, Stocker R: Coexistence of oxidized
lipids and alpha-tocopherol in all lipoprotein density fractions isolated
from advanced human atherosclerotic plaques. Arterioscler Thromb Vasc
Biol 1999, 19(7):1708-1718.
32. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D,
Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL:
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed
oxidation and functional impairment in subjects with cardiovascular
disease. J Clin Invest 2004, 114(4):529-541.
33. Beltowski J, Jamroz-Wisniewska A, Borkowska E, Wójcicka G: Differential
effect of antioxidant treatment on plasma and tissue paraoxonase
activity in hyperleptinemic rats. Pharmacol Res 2005, 51(6):523-532.
34. Zhao SP, Yang J, Li J, Dong SZ, Wu ZH: Effect of niacin on LXRalpha and
PPARgamma expression and HDL-induced cholesterol efflux in
adipocytes of hypercholesterolemic rabbits. Int J Cardiol 2008,
124(2):172-178.
35. Troutt JS, Alborn WE, Mosior MK, Dai J, Murphy AT, Beyer TP, Zhang Y,
Cao G, Konrad RJ: An apolipoprotein A-I mimetic dose-dependently
increases the formation of prebeta1 HDL in human plasma. J Lipid Res
2008, 49(3):581-587.
36. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25(4):402-408.
37. Pirillo A, Uboldi P, Kuhn H, Catapano AL: 15-Lipoxygenase-mediated
modification of high-density lipoproteins impairs SR-BI- and ABCA1-
dependent cholesterol efflux from macrophages. Biochim Biophys Acta
2006, 1761(3):292-300.
38. Speidl WS, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia MJ, Fuster V,
Goldman ME, Badimon JJ: Recombinant apolipoprotein A-I Milano rapidly
reverses aortic valve stenosis and decreases leaflet inflammation in an
experimental rabbit model. Eur Heart J 2010, 31(16):2049-2057.
doi:10.1186/1476-511X-10-210
Cite this article as: Zhong et al.: Probucol alleviates atherosclerosis and
improves high density lipoprotein function. Lipids in Health and Disease
2011 10:210.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhong et al. Lipids in Health and Disease 2011, 10:210
http://www.lipidworld.com/content/10/1/210
Page 9 of 9
